HER2-Positive Breast Cancer Updates

Women Treated for DCIS Live Longer Than Women With No History of DCIS

Results from a study presented at the recently held European Cancer Congress suggest that women treated for ductal carcinoma in situ (DCIS) actually live longer than women who haven’t been diagnosed with DCIS. Overall, women treated for DCIS had a 10% lower risk of dying from any cause compared to women with no history of the disease. The women who had been diagnosed with DCIS did have a higher risk of dying from breast cancer, but a lower risk of dying from most other conditions and other cancers.

BreastCancer.org

Videos

JAMA Oncol

Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial

Eur J Cancer

Long-term Outcome of the REMAGUS 02 Trial, a Multicenter Randomised Phase II Trial in Locally Advanced Breast Cancer Patients Treated With Neoadjuvant Chemotherapy With or Without Celecoxib or Trastuzumab According to HER2 Status

BMJ Open

Efficacy and Safety of Lapatinib and Trastuzumab for HER2-Positive Breast Cancer: a Systematic Review and Meta-Analysis of Randomised Controlled Trials

JAMA Oncol

Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study

BMC Cancer

Development of a Test that Measures Real-Time HER2 Signaling Function in Live Breast Cancer Cell Lines and Primary Cells

View all >

Women Treated for DCIS Live Longer Than Women With No History of DCIS

Perspectives on the Collaborative Management of HER2-Positive Breast Cancer

Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care

Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment

Age and Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer